Impact of Immunotherapies on CNS Outcomes in People with HIV: Potential Benefits, Challenges and Risks
National Institutes of Health
Classification and identifiers
- Solicitation number
- RFA-MH-27-110
- Assistance listing (CFDA)
- 93.242
Amount
Amount not published by the funder
Who can apply
Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations…
About this opportunity
The National Institute of Mental Health (NIMH) intends to publish a notice of funding opportunity (NOFO) to solicit biphasic research applications to evaluate the impact of HIV immunotherapies on central nervous system (CNS) outcomes in people with HIV and to identify mechanisms, benefits, and risks associated with their use in the CNS compartment. The primary goal is to generate evidence that informs whether HIV immunotherapies can safely and effectively target CNS HIV persistence while minimizing neurotoxicity and neuroinflammation. By addressing CNS-specific barriers such as blood brain barrier penetration, compartmentalized viral dynamics, and immune-mediated effects, this NOFO will support the development of strategies that contribute to sustained virologic remission across anatomical...
Related opportunities
- Integrated Specific Pathogen Free Research Models and Human New Approach Methodologies to Advance HIV/AIDS Research (U42 Clinical Trial Not Allowed)National Institutes of HealthUp to $2.7M
- Mechanistic Exploration of Therapeutic Targets and Treatable Traits to Improve CNS Outcomes in People with HIVNational Institutes of Health
- Pilot Studies of Biological, Behavioral and Social Mechanisms Contributing to HIV Pathogenesis Within the Mission of NIDDK (R21 Clinical Trial Not Allowed)National Institutes of HealthCloses Nov 2027
- AIDS Research Center on Mental Health and HIV/AIDS (P30 Clinical Trial Optional)National Institutes of HealthUp to $1.5M
- Early Immune System Development and Ontogeny (R01 Clinical Trial Optional)National Institutes of HealthCloses Nov 2028Up to $400K
- High Priority HIV and Substance Use Research (R01 Clinical Trial Optional)National Institutes of HealthCloses Mar 2027